RUNX
Runt-related transcription factors; RUNX
Runt-related transcription factors (RUNX) is a transcription factor that regulates the bone development, cell growth and tumor metastasis. There are three RUNX transcription factors in mammals: RUNX1, RUNX2 and RUNX3. RUNX1 is expressed in mesenchymal cells and proliferating chondrocytes, and acts as a compensatory factor for RUNX2 to promote the proliferation and differentiation of osteoblasts; RUNX1 is also expressed in hematopoietic cells and certain cancer cells. RUNX2 is expressed in bones and chondrocytes, and is a key regulator of osteoblast differentiation and chondrocyte hypertrophy. RUNX2 is also highly expressed in the nucleus and cytoplasm of prostate cancer cells, that binds to microtubules in the cytoplasm and is associated with the tumor metastasis. RUNX3 is expressed in hypertrophic chondrocytes plays an anabolic function in cartilage metabolism, and maintains the health of cartilage by regulating the expression of genes such as Acan and Prg4. Runt-related transcription factors dysfunction leads to bone diseases like osteoporosis, skeletal abnormality or osteoarthritis. In addition, runt-related transcription factors is abnormal expressed in certain cancer cells, which is supposed to be associated with tumor development[1][2].
References:
- [1]. Hojo H, et al., Runt-related Transcription Factors and Gene Regulatory Mechanisms in Skeletal Development and Diseases. Curr Osteoporos Rep. 2023 Oct;21(5):485-492. [Content Brief]
- [2]. Ashe H, et al., Role of the runt-related transcription factor (RUNX) family in prostate cancer. FEBS J. 2021 Nov;288(21):6112-6126. [Content Brief]
RUNX Isoform Specific Products
All Product Categories
-
RUNX Related Products (20)
Related Products (20)
-
RUNX Isoform Comparison
- 1
-
Ro5-3335
0 ImagesRo5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation.
-
AI-10-49
0 ImagesAI-10-49 is an inhibitor of leukemic oncoprotein CBFβ-SMHHC. AI-10-49 inhibits the binding of CBFβ-SMMHCto the RUNX1 Runt domain with IC50 value of 0.26 μM. AI-10-49 can be used for the research of leukemia.
-
BMP2-derived peptide
0 ImagesBMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research.
-
Segetalin B
0 ImagesSegetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP).
-
Zinc borate
0 ImagesCat. No.: HY-W115785CAS No.: 1332-07-6Zinc borate is a bioactive inorganic substance with properties including osteogenic induction, pro-angiogenesis, antioxidation, antimutagenesis and cytotoxicity. In the field of bone tissue engineering, Zinc borate is often incorporated into chitosan scaffolds. By releasing zinc ions and borate ions, Zinc borate induces the differentiation of human dental pulp stem cells into osteoblasts, upregulates the expression of bone-related genes and promotes calcium deposition. Zinc borate also promotes angiogenesis by upregulating key factors such as vascular endothelial growth factor. Zinc borate exhibits antioxidant capacity to scavenge free radicals, and can specifically reduce mutagenicity under specific conditions. Zinc borate reduces the survival rate of mouse fibroblasts, but it can still be used in studies related to bone tissue engineering.
-
Withanolide B
0 ImagesWithanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.
-
RUNX1/ETO tetramerization-IN-1
0 ImagesRUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC50=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model.
-
Mucic acid
0 ImagesMucic acid is an aldonic acid that can be prepared from pectin. Mucic acid increases the expression level of Runx2, promotes osteoblast differentiation, and upregulates osteogenic differentiation marker genes. Mucic acid can be used to prepare platform compounds, polymers, polymer materials and metal-organic frameworks. Mucic acid is applicable to the research of bone-related defects.
-
AI-10-47
0 ImagesAI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC50 of 3.2 μM.
-
Anhydrous calcium sulfate (97%)
0 ImagesSynonyms: Gypsum ustum (97%)Anhydrous calcium sulfate (97%) serves as an oil-based drilling fluid additive and an osteogenic material. Anhydrous calcium sulfate (97%) increases the plastic viscosity, yield point, apparent viscosity and gel strength of oil-based drilling fluids. Anhydrous calcium sulfate (97%) upregulates the expression of bone-related genes FOSL1, RUNX2 and SPP1. Anhydrous calcium sulfate (97%) significantly affects the behavior of dental pulp stem cells, enhancing their proliferation, differentiation and matrix deposition.
-
AI-4-57
0 ImagesCat. No.: HY-125966CAS No.: 63053-14-5AI-4-57 is an allosteric inhibitor for CBFβ SMMHC-RUNX1 (core binding factor β and the smooth-muscle myosin heavy chain) interaction with an IC50 of 22 μM.
-
RUNX1/ETO-IN-1
0 ImagesCat. No.: HY-174367CAS No.: 923865-06-9RUNX1/ETO-IN-1 is a RUNX1-ETO oncogenic fusion protein inhibitor that specifically targets the NHR2 oligomerization domain. RUNX1/ETO-IN-1 directly interacts with the NHR2 (KD,app = 39 μM). RUNX1/ETO-IN-1 exhibits anti-leukemic activity by inducing apoptosis and promoting differentiation in RUNX1/ETO-translocated AML cells. RUNX1/ETO-IN-1 remains essentially uncharged at physiological pH, demonstrating superior membrane permeability.
-
NSC 140873
0 ImagesCat. No.: HY-118365CAS No.: 106410-13-3NSC 140873 is an inhibitor of the RUNX1-CBFβ interaction. NSC 140873 can be used for research of viral infection and leukemia. NSC 140873 has an unstable structure and can be converted spontaneously in solution to a benzodiazepine (Ro5-3335).
-
Runx1-CBFβ interaction inhibitor 1
0 ImagesCat. No.: HY-124137CAS No.: 493028-20-9Runx1-CBFβ interaction inhibitor 1 is an allosteric inhibitior of Runt domain-CBFb interaction (IC50=3.2 μM).
-
Largazole
0 ImagesCat. No.: HY-13906CAS No.: 1009815-87-5Synonyms: (+)-LargazoleLargazole ((+)-Largazole) is an orally active, blood-brain barrier-permeable class I histone deacetylase (HDAC) inhibitor with in vivo anticancer activity and osteogenic efficacy. As a prodrug, Largazole hydrolyzes to Largazole thiol (HY-170890), which has a Ki value of 0.07 nM against human HDAC2. Largazole regulates the cell cycle, induces apoptosis, upregulates tumor suppressors and osteoblast differentiation markers, inhibits osteoclast formation, and upregulates neuroprotection-related genes. Largazole can be used in the research of various cancers including colorectal cancer, as well as neurodegenerative diseases.
-
Withanolide B (Standard)
0 ImagesCat. No.: HY-129566RCAS No.: 56973-41-2Withanolide B (Standard) is the analytical standard of Withanolide B. This product is intended for research and analytical applications. Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.
-
Mucic acid (Standard)
0 ImagesMucic acid (Standard) is the analytical standard of Mucic acid (HY-W014410). This product is intended for research and analytical applications. Mucic acid is an aldonic acid that can be prepared from pectin. Mucic acid increases the expression level of Runx2, promotes osteoblast differentiation, and upregulates osteogenic differentiation marker genes. Mucic acid can be used to prepare platform compounds, polymers, polymer materials and metal-organic frameworks. Mucic acid is applicable to the research of bone-related defects.
-
Ro5-3335 (Standard)
0 ImagesCat. No.: HY-108470RCAS No.: 30195-30-3Ro5-3335 (Standard) is the analytical standard of Ro5-3335 (HY-108470). This product is intended for research and analytical applications. Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation.
-
Anti-osteoporosis agent-6
0 ImagesCat. No.: HY-155985CAS No.: 445231-36-7Anti-osteoporosis agent-6 (compound 174) is an anti-osteoporosis agent. Anti-osteoporosis agent-6 has 14.11% inhibition rate against osteoclast formation at 10 μM.
- 1
